In Brief: FDA's Medical Imaging Drugs Advisory Committee
This article was originally published in The Gray Sheet
Executive Summary
FDA's Medical Imaging Drugs Advisory Committee: Meeting July 22 at the Holiday Inn-Bethesda in Bethesda, Maryland. The committee will review Cytogen's Prostascint product license application, according to the June 24 Federal Register. Prostascint is a "radiolabeled monoclonal antibody designed to detect sites of metastatic cancer which express the prostate specific membrane antigen." For more information, contact FDA's William Freas or Sheila Langford, 301/827-0314...